Scotiabank analyst Sung Ji Nam last night initiated coverage of Guardant Health with an Outperform rating and $36 price target. The analyst started coverage on nine companies in the life science tools and diagnostics space with a positive view on the sector. Guardant is a pioneer and leader in developing and commercializing liquid biopsy-based tests for precision oncology, Ji Nam tells investors in a research note. Guardant360 tests for advanced cancer should continue to drive near-term growth, the analyst adds.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GH:
